Navigation Links
Cambrex Reports Second Quarter of 2011 Results
Date:8/2/2011

rough Wednesday, August 10, 2011 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 1438939 to access the replay.  

Forward Looking StatementsThis document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected performance, especially expectations with respect to sales, gross margins, operating expenses, earnings per share, cash flows, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities.  These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2010, captioned "Risk Factors," or otherwise described in the Company's filings with the Securities and Exchange Commission, as well as any cautionary language in the Company's Annual Report on Form 10-K for the period ended December 31, 2010, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectable receivables, loss on disposi
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cambrex Reports Third Quarter 2010 Results
2. Cambrex Reports Fourth Quarter and Full Year 2009 Results
3. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
4. Cambrex Reports First Quarter 2009 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports Third Quarter 2008 Results
7. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
8. Gen-Probe Reports Financial Results for the Second Quarter of 2011
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
11. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... for cancer, today announced the appointment of Thomas C Reynolds ... over 20 years, development experience gained in the biotechnology industry, ... "I am delighted to welcome Tom at this transformative ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... 2011  Amgen (NASDAQ: AMGN ) announced that its ... for the first quarter of 2012. This represents an approximate 29 ... The dividend will be paid on March 7, 2012 to ... on Feb. 15, 2012.  About Amgen ...
... Inc. (PDL) (NASDAQ: PDLI ) today announced that ... payment of $0.15 per share to all stockholders owning shares ... (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO )   ... humanization of monoclonal antibodies and, by doing so, enabled the ...
... tune and enhance thermal conductivity a basic property generally ... engineers a new tool for managing thermal effects in smart ... devices. The finding was made by a group of ... at Vanderbilt University, and published online in the journal ...
Cached Biology Technology:Amgen Announces 2012 First Quarter Dividend 2Amgen Announces 2012 First Quarter Dividend 3New method for enhancing thermal conductivity could cool computer chips, lasers and other devices 2New method for enhancing thermal conductivity could cool computer chips, lasers and other devices 3
(Date:7/9/2014)... cell divides, it must first make a copy of its ... that occurs billions of times a day in the human ... tools that cells use to replicate DNAthe enzymes that unzip ... a clear picture of how the process works. , Now, ... to decipher what goes on at the "replication fork"the point ...
(Date:7/8/2014)... reefs and the animals that depend on them relies ... sea creature to get fatand to be flexible about ... the first study of its kind, scientists at The ... live symbiotically with algaeare better able to recover from ... keep large energy reservesmostly as fatsocked away in their ...
(Date:7/8/2014)... increased risk of severe perineal tearing during childbirth in women ... a new study published today (9 July) in BJOG: ... This study, investigates among women who have had a third ... subsequent pregnancies and the recurrence of severe perineal tears. ... in some women the tear may be more extensive. A ...
Breaking Biology News(10 mins):Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4For corals adapting to climate change, it's survival of the fattest -- and most flexible 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 3For corals adapting to climate change, it's survival of the fattest -- and most flexible 4Mode of delivery following a perineal tear and recurrence rate in subsequent pregnancies 2
... of corals are likely to succeed at the expense of ... in the Cell Press journal Current Biology that ... "The good news is that, rather than experiencing wholesale ... the mix of coral species as the ocean warms and ...
... genomes, says a new study of poison frogs from ... changes over time, but the rate at which those ... Juan C. Santos of the National Evolutionary Synthesis Center ... trying to explain why some species have faster-changing genomes ...
... ARLINGTON, Va.The deafening roar of supersonic aircraft can cause ... so the Office of Naval Research (ONR) is funding ... announced April 12. "The noise problem falls into ... noise impact on the communities surrounding air bases," said ...
Cached Biology News:Under climate change, winners and losers on the coral reef 2Athletic frogs have faster-changing genomes 2ONR taps research teams to help reduce jet noise 2
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
X-gal,1g...
...
Biology Products: